At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Tislelizumab +1 morebiological
Likely dose
Tislelizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-1 Trial)
In Brief
A Phase 2 clinical trial evaluating Tislelizumab and Afatinib for Head and Neck Cancer. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The purpose of this study is to explore the efficiency and safety of anti-Programmed death-1 (PD-1) immunotherapy, tislelizumab, combined with EGFR-tyrosine kinase inhibitor (TKI), afatinib as a new neoadjuvant treatment regimen for patients with resectable head and neck squamous cell carcinoma (HNSCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartSep 2022
Primary CompletionDec 2023
Study CompletionJul 2024
TodayJul 2026
First PostedAug 26, 2022
Enrollment StartSep 19, 2022
Primary CompletionDec 31, 2023
Study CompletionJul 31, 2024
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 3.8 years ago
Interventions
Tislelizumabbiological
200mg IV Q3W
Afatinibdrug
30mg PO QD